Needham analyst Gil Blum initiated coverage of Recursion Pharmaceuticals (RXRX) with a Buy rating and $17 price target. The company takes a fundamentally different approach to drug development by using a fully automated generator of millions of biological experiments and applying artificial intelligence to identify non-obvious relationships and novel biology, the analyst tells investors in a research note. Needham adds that Recursion Pharmaceuticals’ reliance on creating an ever-green pipeline of Pharma collaborations should be the key value driver for the company, with the internal pipeline serving as a proof-of-concept. With partners that include Bayer (BAYRY) and Roche (RHHBY), Recursion’s total potential revenue from Pharma partners is significantly higher than that of its peers, Needham states.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on RXRX:
- Recursion Pharmaceuticals says no accounts held with Silicon Valley Bank
- ‘Too Cheap to Ignore’: Cathie Wood Snaps Up These 2 Stocks Under $10
- Recursion Pharmaceuticals reports Q4 EPS (31c), consensus (29c)
- Community Leaders Unite to Provide Support and Resources for Thousands of Utahns with Rare Diseases